BioMarin, MSD sue Aurobindo over rare disease drug

BioMarin Pharmaceutical and MSD (known as 'Merck & Co' in the US), have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan (Sapropterin hydrochloride), used to treat a rare genetic disorder.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

MSD hit with €39m fine over contraceptive generic delay

26 October 2022 The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

Americas

BioMarin accuses engineer of stealing 1,800 files

23 November 2021 BioMarin Pharmaceuticals has accused a former engineer who went to work for competitor Sangamo Therapeutics of stealing more than 1,800 files containing confidential information and trade secrets.

Americas

Sarepta and Biomarin resolve patent dispute with $35m licence

20 July 2017 Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

BioMarin, MSD sue Aurobindo over rare disease drug

More on this story

Editor's picks

Editor's picks

More features